Also Known As
ERBB2
HER2/neu
c-erbB-2
erb-b2 receptor tyrosine kinase 2
Human epidermal growth factor receptor 2
Formal Name
HER2(ERBB2) Amplification; HER2(ERBB2) Overexpression
This article was last reviewed on
This article waslast modified on July 19, 2018.
At a Glance
Why Get Tested?

To determine whether a tumor is positive for particular HER2 (ERBB2) mutations, which helps to guide treatment and predict the course of the disease (prognosis); sometimes to monitor treatment and for cancer recurrence

When To Get Tested?

When you have been diagnosed with invasive breast cancer or you had an invasive breast cancer that was treated but the tumor reoccurs or spreads (metastasizes), or when you have been diagnosed with certain types of stomach and esophagus cancer that are inoperable, locally advanced, recurrent, or metastatic

Sample Required?

A sample of tumor tissue is obtained by doing a fine needle aspiration, needle biopsy, or surgical biopsy (a tumor removed surgically)

Test Preparation Needed?

Before a biopsy, the physician who will obtain the sample of tumor tissue will provide instructions.

You may be able to find your test results on your laboratory's website or patient portal. However, you are currently at Lab Tests Online. You may have been directed here by your lab's website in order to provide you with background information about the test(s) you had performed. You will need to return to your lab's website or portal, or contact your healthcare practitioner in order to obtain your test results.

Lab Tests Online is an award-winning patient education website offering information on laboratory tests. The content on the site, which has been reviewed by laboratory scientists and other medical professionals, provides general explanations of what results might mean for each test listed on the site, such as what a high or low value might suggest to your healthcare practitioner about your health or medical condition.

The reference ranges for your tests can be found on your laboratory report. They are typically found to the right of your results.

If you do not have your lab report, consult your healthcare provider or the laboratory that performed the test(s) to obtain the reference range.

Laboratory test results are not meaningful by themselves. Their meaning comes from comparison to reference ranges. Reference ranges are the values expected for a healthy person. They are sometimes called "normal" values. By comparing your test results with reference values, you and your healthcare provider can see if any of your test results fall outside the range of expected values. Values that are outside expected ranges can provide clues to help identify possible conditions or diseases.

While accuracy of laboratory testing has significantly evolved over the past few decades, some lab-to-lab variability can occur due to differences in testing equipment, chemical reagents, and techniques. This is a reason why so few reference ranges are provided on this site. It is important to know that you must use the range supplied by the laboratory that performed your test to evaluate whether your results are "within normal limits."

For more information, please read the article Reference Ranges and What They Mean.

What is being tested?

HER2 is short for the human epidermal growth factor receptor 2. (It is also known as ERBB2). In some cancers, especially breast cancer or cancers of the stomach and esophagus (gastroesophageal), the tumor cells have extra copies of the gene and excess amounts of the protein that it produces. Tumors in this category are known as HER2-positive and can be more aggressive and respond differently to treatment than HER2-negative tumors. The HER2 test performed on tumor samples determines whether a person's cancer is HER2-positive.

In normal cells, the HER2 gene codes for a protein that helps promote cell growth. When a mutation results in too many copies within a cell (amplification), HER2 then produces too much of the HER2 protein, causing HER2 to act as an oncogene, meaning that it can promote uncontrolled, cancerous growth. This happens in about one in five breast cancers and can also occur in other cancers, such as stomach and esophagus cancers.

The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) jointly recommend that the tumors of all people with invasive or recurrent breast cancer be tested for HER2. Invasive breast cancer is cancer that has spread from the ducts or lobules to other parts of the breast or to immediately adjacent tissues or organs. Similarly, ASCO and CAP recommend that patients with certain stomach and esophagus cancers (inoperable, locally advanced, recurrent or metastatic) who may also benefit from HER2-targeted therapy have their tumor tissue tested.

To determine if a tumor is positive for HER2, a sample of tumor is tested. There are two established ways to test HER2 status:

  • Immunohistochemistry (IHC) measures the amount of HER2 protein present.
  • Fluorescent in situ hybridization (FISH) looks at the gene level for the number of copies of the gene present; an increased number of gene copies is known as amplification.

Both IHC and FISH are acceptable testing methods for breast cancer. ASCO and CAP do not express a preference for one over the other, but if one test is equivocal (not clearly positive or negative), then the other should be done as a follow-up test for clarification of the result. For stomach and esophagus cancers, IHC is done first and FISH is reserved for follow-up clarification of equivocal IHC results.

An alternative testing method, chromogenic in situ hybridization (CISH), is also available but isn't commonly used.

Accordion Title
Common Questions
  • How is the test used?

    Breast tumor
    After a person has been diagnosed with invasive or recurrent breast cancerHER2 tissue testing is used to determine whether the tumor is HER2-positive. Someone with a HER2-positive tumor may benefit from HER2-targeted therapy.

    Testing may also be used as a prognostic marker to help determine how aggressive the breast cancer is likely to be. It is not diagnostic but helps healthcare practitioners determine treatment options and understand more about the tumor's characteristics. Tumors that are HER2-positive tend to grow more aggressively and breast cancers with this abnormality resist endocrine (anti-hormone) therapy and some standard chemotherapies. People with HER2-positive breast cancers tend to have a poorer prognosis, but this tumor characteristic also makes them candidates to receive treatment specific for HER2-positive cancers, also known as targeted therapy.

    HER2 testing is usually ordered along with estrogen and progesterone hormone receptor status tests (ER and PR). The results of these tests provide information about the person's likely prognosis and response to specific therapies, such as hormone therapy and chemotherapy.

    Stomach and esophagus (gastroesophageal) tumor
    For patients with inoperable, advanced, recurrent, or metastatic cancer of the stomach or esophagus who are candidates for HER2-targeted therapy, assessment of tumor HER2 overexpression is recommended to determine if trastuzumab (Herceptin) may be effective as part of their treatment.

  • When is it ordered?

    HER2 tissue testing is recommended along with other tests, such as estrogen and progesterone receptor status testing, as part of an initial workup of invasive breast cancer. Testing is also done when breast cancer has spread to other parts of the body (metastatic) or when a person has been successfully treated but the cancer has come back (recurrent breast cancer). In its 2015 guidelines on biomarker testing of metastatic breast cancer, ASCO recommends offering HER2 testing to everyone with accessible metastases. However, there is not enough evidence to know if changing treatment based on the test will affect an individual's outcome in this setting.

    HER2 tissue testing is also recommended for patients with inoperable, advanced, recurrent, or metastatic adenocarcinoma of the stomach or esophagus who are candidates for HER2-targeted therapy.

  • What does the test result mean?

    Breast Cancer
    HER2-positive breast cancer means the individual tested is likely to have a tumor that is aggressive, will respond poorly to endocrine treatment, and will be resistant to standard chemotherapy. The person may be considered a candidate for HER2-targeted therapy, such as trastuzumab, lapatinib or pertuzumab.

    If HER2 testing is negative or equivocal by one method (IHC or FISH), then the other method is performed. If the second test is positive, the person still may benefit from HER2-targeted therapy.

    If the tumor is HER2-negative, then HER2-targeted therapy isn't expected to be effective and the individual tested will avoid unnecessary side effects from treatment that is unlikely to help.

    Stomach and esophagus cancers
    Addition of HER2-targeted therapy in patients with HER2-positive advanced cancers of the stomach and esophagus can result in improved survival and quality of life.

    If HER2 testing is equivocal or negative by IHC, then FISH may be performed. If FISH is positive, then the person still may benefit from HER2-targeted therapy.

    If the tumor is HER2-negative, then adding HER2-targeted therapy is unlikely to be effective.

  • Is there anything else I should know?

    Sometimes, results of testing for a sample are inadequate or inconclusive. In this case, repeat testing using another sample may be necessary.

    HER2 testing is not available in every laboratory. Both IHC and FISH methods require experience and special training to perform and interpret. The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) have recommended guidelines for HER2 testing to ensure accuracy. Your healthcare provider may send your sample to a reference laboratory and the results may take several weeks to return.

    Certain HER2-positive tumors are susceptible to treatment with HER2-targeted drugs. HER2-targeted therapy may be used alone or with some other chemotherapy agents and is typically used to treat only people who have HER2-positive tumors. If the initial HER2-targeted drug is not effective in someone with a HER2-positive tumor, then the patient may be offered another drug also designed to target HER2.

    A test that measures HER2 in one's blood is also available. At present there isn't wide consensus that it is as useful for most patients; therefore it isn't routinely recommended.

  • Besides HER2, what other laboratory tests may my healthcare provider order on my breast cancer tissue?

    During an initial workup of invasive breast cancer, the pathologist evaluating the tumor will also test the tissue for estrogen and progesterone hormone receptor status (ER and PR). Tumors with positive estrogen and/or progesterone receptor status may have a diminished response to endocrine/hormone therapy if the tumor is also HER2-positive. Your healthcare practitioner may also order a breast cancer gene expression test to learn more about your cancer's characteristics.

  • Does HER2-targeted therapy work for every tumor that is HER2-positive?

    No. However, HER2-targeted therapy may be combined with other chemotherapy agents to increase effectiveness in many circumstances.

  • Would this testing also be performed on a man?

    Yes. Men do not get breast cancer as frequently as women, but it does occur and their cancer may also be HER2-positive. Guidelines also recommend HER2 testing for clinical decision-making in patients of any gender with advanced stomach and esophagus cancers who are potential candidates for HER2-targeted therapy.

View Sources

Sources Used in Current Review

Wang, J. (2013). Bringing cancer serological diagnosis to a new level. Future Oncology. Available online at http://www.medscape.com/viewarticle/776799_3. Accessed Jan 2018.

(October 2013) Wolff A, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Journal of Clinical Oncology. Available online at http://ascopubs.org/doi/abs/10.1200/JCO.2013.50.9984?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed. Accessed Jan 2018.

Perez, E.A. et al (2014 November). Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. Journal of Clinical Oncology. Available online at http://ascopubs.org/doi/full/10.1200/JCO.2014.55.5730. Accessed Jan 2018.

Poznak, C.V. (2015 August). Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. Available online at http://ascopubs.org/doi/full/10.1200/jco.2015.61.1459. Accessed Jan 2018.

Markman, M. (2018 Jan 15). Breast Cancer and HER2, Overview of HER2 breast cancer. Medscape. Available online at http://emedicine.medscape.com/article/1689966-overview. Accessed Jan 2018.

(© 2016). National Breast Cancer Foundation. Lab Tests. Available online at http://www.nationalbreastcancer.org/breast-cancer-lab-tests. Accessed Jan 2018.

Harris, L. et al. (2016 April). Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-state invasive breast cancer: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology. Available online at http://ascopubs.org/doi/pdf/10.1200/jco.2015.65.2289. Accessed Jan 2018.

(Reviewed 2016 June 1). Breast cancer HER2 status. American Cancer Society. Available online at https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-her2-status.html. Accessed Jan 2018.

Denduluri, N. et al. (2016 July). Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) –Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. Journal of Clinical Oncology. Available online at http://ascopubs.org/doi/full/10.1200/JCO.2016.67.0182. Accessed Jan 2018.

Reix, N. (2016 October 5). A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression. Available online at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065601/. Accessed Jan 2018.

(Reviewed 2017 April) HER2/neu testing. Quest Diagnostics. Available online at http://www.questdiagnostics.com/testcenter/testguide.action?dc=CF_HER_2. Accessed Jan 2018.

Chalsasani, P. (Updated 2017 June 27). Breast cancer workup. Medscape. Available online at http://emedicine.medscape.com/article/1947145-workup#aw2aab6b5b6. Accessed Jan 2018.

Factor, R. E. (Updated 2017 July). Breast cancer. Arup Consult. Available online at https://arupconsult.com/content/breast-cancer/?tab=tab_item-6. Accessed Jan 2018.

American Cancer Society. Targeted Therapy for Breast Cancer. Available online at https://www.cancer.org/cancer/breast-cancer/treatment/targeted-therapy-for-breast-cancer.html. Accessed Jan 2018.

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr; American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007 Nov 20;25(33):5287-312.

Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-Angulo AM, Hicks DG, Hill EG, Liu MC, Lucas W, Mayer IA, Mennel RG, Symmans WF, Hayes DF, Harris LN. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2015 Aug 20;33(24):2695-704. doi: 10.1200/JCO.2015.61.1459.

Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Bast RC, Hayes DF; American Society of Clinical Oncology. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016 Apr 1;34(10):1134-50. doi: 10.1200/JCO.2015.65.2289.

Lam L, McAndrew N, Yee M, Fu T, Tchou JC, Zhang H. Challenges in the clinical utility of the serum test for HER2 ECD. Biochim Biophys Acta. 2012 Aug;1826(1):199-208. doi: 10.1016/j.bbcan.2012.03.012.

Tsé C, Gauchez AS, Jacot W, Lamy PJ. HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer. Cancer Treat Rev. 2012 Apr;38(2):133-42. doi: 10.1016/j.ctrv.2011.03.008.

Di Gioia D, Dresse M, Mayr D, Nagel D, Heinemann V, Stieber P. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer. Clin Chim Acta. 2015 Feb 2;440:16-22. doi: 10.1016/j.cca.2014.11.001.

Lee SB, Lee JW, Yu JH, Ko BS, Kim HJ, Son BH, Gong G, Lee HJ, Kim SB, Jung KH, Ahn JH, Lee W, Sung J, Ahn SH. Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer. BMC Cancer. 2014 Dec 10;14:929. doi: 10.1186/1471-2407-14-929.

Mishra R, Hanker AB, Garrett JT. Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget. 2017 Nov 30;8(69):114371-114392. doi: 10.18632/oncotarget.22825.

Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB 3rd, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2016 Dec;140(12):1345-1363.

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF; American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014 Feb;138(2):241-56. doi: 10.5858/arpa.2013-0953-SA.

NCCN Guidelines for Patients, Breast Cancer, Early Stage, Version 1.2016. Available online at https://www.nccn.org/patients/guidelines/stage_i_ii_breast/files/assets/basic-html/page-1.html. Accessed June 2018.

NCCN Guidelines for Patients, Stomach Cancer, Version 1.2016. Available online at https://www.nccn.org/patients/guidelines/cancers.aspx#stomach. Accessed June 2018.

Sources Used in Previous Reviews

Thomas, Clayton L., Editor (1997). Taber's Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, PA [18th Edition].

Pagana, Kathleen D. & Pagana, Timothy J. (2001). Mosby's Diagnostic and Laboratory Test Reference 5th Edition: Mosby, Inc., Saint Louis, MO.

Check, W. (2002 February). Making the call on HER2 testing methods. CAP Today, In the News [On-line journal]. Available online at http://www.cap.org/html/publications/feature.html.

Check, W. (2002 February). Serum HER2 testing. CAP Today, In the News [On-line journal]. Available online at http://www.cap.org/html/publications/sidebar1.html.

ASCO (1996). c-erbB-2 as a Marker for Breast Cancer. American Society for Clinical Oncology [On-line guideline]. Available online at http://www.asco.org/prof/pp/html/guide/tumor/m_tumor14.htm.

ACS (2001). Immunotherapy with Trastuzumab (Herceptin). American Cancer Society [On-line information]. Available online through http://www.cancer.org.

ACS (2001). How is Breast Cancer Diagnosed? American Cancer Society, Cancer Reference Information [On-line information]. Available online through http://www.cancer.org.

Locke, J. (2001 February). HER2/neu Testing. American Association for Clinical Chemistry, Strategies [Newsletter]. Available through AACC (http://www.aacc.org)

Yazifi, H., and Gown, A. (2002 June). Controversies and guidelines in tissue-based HER-2/neu testing in breast cancer. Medical Laboratory Observer [Journal], Vol. 34 (6), pp 12-16,20. Available through MLO (http://www.mlo-online.com)

MEDCEU (1999). Breast Cancer and HER2. MEDCEU [On-line continuing education]. Available online at http://www.medceu.com/course-no-test.cfm?CID=307.

Pagana, K. D. & Pagana, T. J. (© 2007). Mosby's Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO. Pp 200-202.

Wu, A. (© 2006). Tietz Clinical Guide to Laboratory Tests, 4th Edition: Saunders Elsevier, St. Louis, MO. Pp 548-551.

Hicks, D. and Kulkarni, S. (2008 April 14). HER2+ Breast Cancer: Review of Biologic Relevance and Optimal Use of Diagnostic Tools. Medscape from American Journal of Clinical Pathology [On-line information]. Available online at http://www.medscape.com/viewarticle/570732. Accessed July 2009.

Markman, M. (2009 June 30, Updated). Breast Cancer and HER2. Emedicine [On-line information]. Available online at http://emedicine.medscape.com/article/1689966-overview. Accessed July 2009.

(2009 May, Updated). Breast Cancer Management Assays. ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/Topics/OncologicDz/GynecologicalTumors/BreastCancerManagement.html#. Accessed July 2009.

(2008 December 02). NCCN Clinical Practice Guidelines in Oncology, Breast Cancer v.1.2009 Medscape from National Comprehensive Cancer Network [On-line information]. PDF available for download at http://misc.medscape.com/images/586/406/Breast-Medscape.pdf. Accessed July 2009.

(2006 December). What to Know: ASCO's Guideline on HER2 Testing for Breast Cancer. American Society of Clinical Oncologists [On-line information]. Available online through http://www.cancer.net. Accessed July 2009.

Esteva, F. et. al. (2005 May 13). Clinical Utility of Serum HER2/neu in Monitoring and Prediction of Progression-Free Survival in Metastatic Breast Cancer Patients Treated With Trastuzumab-Based Therapies. Medscape from Breast Cancer Research [On-line information]. Available online at http://www.medscape.com/viewarticle/503103. Accessed July 2009.

Tse, C. et. al. (2005). Evaluation of the Quantitative Analytical Methods Real-Time PCR for HER-2 Gene Quantification and ELISA of Serum HER-2 Protein and Comparison with Fluorescence in Situ Hybridization and Immunohistochemistry for Determining HER-2 Status in Breast Cancer Patients. Clinical Chemistry. 2005;51:1093-1101 [On-line information]. Available online at http://www.clinchem.org/cgi/reprint/51/7/1093. Accessed July 2009.

Zidan J, Dashkovsky I, Stayerman C, et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer. 2005 Sep 5;93(5):552-6.

Lower EE, Glass E, Blau R, Harman S. HER-2/neu expression in primary and metastatic breast cancer. 1: Breast Cancer Res Treat. 2009 Jan;113(2):301-6. Epub 2008 Feb 14.

Carney WP, Brown-Shimer S, Hamer PJ. Serum HER-2/neu testing can identify HER-2/neu positive patients previously classified as negative by tissue testing. American Association for Clinical Chemistry Annual Meeting Proceedings, 2008. Clin Chem Vol 54(56) Suppl, Pg A130: Abstract No. C-96.

Schwartz MK, et al. International Journal of Biological Markers 2000;15(4):324.

Lipton A, et al. Journal of Clinical Oncology 2002;20(6):1467.

Esteva FJ, et al. Journal of Clinical Oncology 2002;20(7):1800.

Lipton et al. Serial Serum HER2/neu Levels and Clinical Response Status for Study EGF20009 - Metastatic Breast Cancer, Sept 7th 2007, ASCO Breast Cancer Meeting, San Francisco.

Serum HER-2/neu and Relative Resistance to TRASTUZUMAB-based Therapy in Patients With Metastatic Breast Cancer. Cancer 2008; 113:1294-1301.

(Updated July 2013). Breast Cancer Workup. Medscape reference. Available online at http://emedicine.medscape.com/article/1947145-workup#aw2aab6b5b6. Accessed July 2013.

Ithimakin, Suthinee et al. HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab. Cancer Research. February 2013. Available online at http://cancerres.aacrjournals.org/content/early/2013/02/14/0008-5472.CAN-12-3349.abstract. doi: 10.1158/0008-5472.CAN-12-3349 Accessed July 2013.

(Copyright 2012). Breast Cancer and Breast Pathology. John Hopkins University. Available online at http://pathology.jhu.edu/breast/biomarker-testing.php. Accessed July 2013.

(Updated December 2012) HER2/neu Testing. Quest Diagnostics. Available online at http://www.questdiagnostics.com/testcenter/testguide.action?dc=CF_HER_2. Accessed July 2013.

Markman, M. (2013 February 13, Updated). Breast Cancer and HER2. Emedicine [On-line information]. Available online at http://emedicine.medscape.com/article/1689966-overview. Accessed July 2013.

Breast Cancer Management Assays. ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/Topics/BreastCancer.html. Accessed July 2013.

(Updated 2013). HER2 Testing: Summary for Breast Cancer Patients. Available online at http://www.nccn.com/about-us/61-symptoms-category.html. Accessed July 2013.

(©2012). What to Know: ASCO's Guideline on HER2 Testing for Breast Cancer. American Society of Clinical Oncologists. Available online at http://www.cancer.net/publications-and-resources/what-know-ascos-guidelines/what-know-ascos-guideline-her2-testing-breast-cancer. Accessed July 2013.

(Updated June 2011). Serum HER2 Testing. Atlantic Health System. Available online at https://atlantichealth.dnadirect.com/grc/patient-site/her2-serum/index.html. Accessed July 2013.

(November 2008) ARUP Laboratories Technical Bulleting. HER-2/neu Serum For monitoring soluble HER-2/neu protein in patients with metastatic breast cancer. Available online at http://www.aruplab.com/Testing-Information/resources/TechnicalBulletins/HER-2neu%20Serum.pdf. Accessed August 2013.

Carney W, et al. Potential Clinical Utility of Serum HER-2/neu Oncoprotein Concentrations in Patients with Breast Cancer. Clinical Chemistry, October 2003 vol. 49 no. 10 1579-1598. Available online at http://www.clinchem.org/content/49/10/1579.short. Accessed August 2013.

(October 2013) Wolff A, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Available online at http://www.asco.org/quality-guidelines/recommendations-human-epidermal-growth-factor-receptor-2-testing-breast-cancer. Accessed October 2013.

Lam L, et al. Challenges in the clinical utility of the serum test for HER2 ECD. Biochim Biophys Acta. 2012 August; 1826(1): 199–208. Available online at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362659/. Accessed October 2013.

Gregory J. Tsongalis, PhD, HCLD, CC, Professor of Pathology, Director, Molecular Pathology, Dartmouth Hitchcock Medical Center and Geisel School of Medicine at Dartmouth, Lebanon, NH.

Ask a Laboratory Scientist

 

Your questions will be answered by a laboratory scientist as part of a voluntary service provided by one of our partners, the American Society for Clinical Laboratory Science (ASCLS). Click on the Contact a Scientist button below to be re-directed to the ASCLS site to complete a request form. If your question relates to this web site and not to a specific lab test, please submit it via our Contact Us page instead. Thank you.

Contact a Scientist